Faculty Bibliography

Try a new search

Format these results:

Searched for:

in-biosketch:true

person:zelefm01

Total Results:

482

Journal of clinical oncology. 2022:40(6).DOI:

Favorable toxicity of chemoradiation for muscle-invasive bladder cancer in elderly, frail patients. [Meeting Abstract]

Moore, Assaf; Zhang, Zhigang; Bochner, Bernard H.; Donahue, Timothy F.; Rosenberg, Jonathan E.; Iyer, Gopa; Funt, Samuel Aaron; Bajorin, Dean F.; Teo, Min Yuen; Aggen, David Henry; Gorovets, Daniel; Guttmann, David; Zelefsky, Michael J.; Kollmeier, Marisa
ISI:000771008900514
ISSN: 0732-183x
CID: 5531312
International journal of radiation oncology biology physics. 2022:114(3):E213-E214.DOI:

Focal Dose Intensification to the Dominant Intraprostatic Lesion (DIL) Using an MR-Linac Adaptive-Planning Approach for Prostate Cancer: Dosimetric Outcomes and Early Toxicity [Meeting Abstract]

Brennan, V. S.; Burleson, S.; Kostrzewa, C.; Scripes, P. G.; Subashi, E.; Zhang, Z.; Tyagi, N.; Zelefsky, M. J.
ISI:000892639300461
ISSN: 0360-3016
CID: 5531332
International journal of radiation oncology biology physics. 2022:114(3):S92-S92.DOI:

Superior Post-Treatment Biopsy Outcomes with High Dose SBRT Compared to High-Dose Conventionally Fractionated IMRT for Clinically Localized Prostate Cancer [Meeting Abstract]

Zelefsky, M. J.; Kollmeier, M. A.; White, C.; Zhang, Z.; Reuter, V.; Ehdaie, B.; Moore, A.; Samson, F.; Gorovets, D.; Damato, A. L.; Elsayegh, A.; McBride, S. M.
ISI:000892639302209
ISSN: 0360-3016
CID: 5531392
Radiotherapy & oncology. 2022:170:S500-S501.DOI:

Determining interobserver variability in prostate bed CTV target delineation using MRI [Meeting Abstract]

Sritharan, K.; Akhiat, H.; Cahill, D.; Choi, S. L.; Choudhury, A.; Chung, P.; Diaz, J.; Dysager, L.; Hall, W.; Kerkmeijer, L.; Lawton, C. A.; Murray, J.; Nyborg, C. J.; Pos, F. J.; Rigo, M.; Schytte, T.; Sidhom, M.; Sohaib, A.; Tan, A.; van Zyp, J. van der Voort; Vesprini, D.; Zelefsky, M. J.; Tree, A.
ISI:000806764200144
ISSN: 0167-8140
CID: 5531322
International journal of radiation oncology biology physics. 2022:114(3):E222-E223.DOI:

A Novel Approach to Vessel-Sparing Prostate Radiotherapy Using MR-Only Simulation and Non-Contrast MR Angiography: Vessel Delineation Feasibility and SBRT Dosimetric Analysis [Meeting Abstract]

Haseltine, J.; Tyagi, N.; Burleson, S.; Akin, O.; Zelefsky, M. J.
ISI:000892639300480
ISSN: 0360-3016
CID: 5531352
International journal of radiation oncology biology physics. 2022:114(3):E226-E226.DOI:

Combined Brachytherapy and Ultra-Hypofractionated Radiotherapy for Intermediate-Risk Prostate Cancer: Comparison of Toxicity Outcomes Using a High-Dose Rate (HDR) vs. Low-Dose Rate (LDR) Brachytherapy Boost [Meeting Abstract]

Kollmeier, M. A.; Gorovets, D.; Flynn, J.; McBride, S.; Brennan, V. S.; Beaudry, J.; Cohen, G.; Damato, A. L.; Zhang, Z.; Zelefsky, M. J.
ISI:000892639300487
ISSN: 0360-3016
CID: 5531362
Journal of clinical oncology. 2022:40(6).DOI:

Discordance of patient- and physician-reported toxicities in two prospective trials of stereotactic body radiotherapy (SBRT) for localized prostate cancer. [Meeting Abstract]

Patel, Akshat; Badia, Rohit R.; Amini, Armon; Kung, Christopher; Kusin, Samuel B.; Neufeld, Sarah; Mannala, Samantha; Garant, Aurelie; Hannan, Raquibul; Timmerman, Robert D.; Zelefsky, Michael J.; Folkert, Michael Ryan; Desai, Neil Bipinchandra
ISI:000771008900250
ISSN: 0732-183x
CID: 5531302
International journal of radiation oncology biology physics. 2022:114(3):E217-E218.DOI:

Salvage Prostate Brachytherapy in Radiorecurrent Prostate Cancer: An International Delphi Consensus Study [Meeting Abstract]

Corkum, M. T.; Buyyounouski, M. K.; Chang, A. J.; Chung, H. T.; Chung, P.; Cox, B. W.; Crook, J. M.; Davis, B. J.; Frank, S. J.; Lopez, I. Henriquez; Horwitz, E. M.; Hoskin, P.; Hsu, I. C. J.; Keyes, M.; King, M. T.; Kollmeier, M. A.; Krauss, D. J.; Kukielka, A.; Morton, G.; Orio, P. F., III; Pieters, B.; Potters, L.; Rossi, P. J.; Showalter, T. N.; Solanki, A. A.; Song, D.; Vanneste, B.; Vigneault, E.; Wojcieszek, P. A.; Zelefsky, M. J.; Kamrava, M.
ISI:000892639300469
ISSN: 0360-3016
CID: 5531342
Frontiers in oncology. 2022:12.DOI: 10.3389/fonc.2022.975519

Radiation therapy for de novo anorectal cancer in patients with a history of prostate radiation therapy

Hilal, Lara; Wu, Abraham J; Reyngold, Marsha; Cuaron, John J; Navilio, John; Romesser, Paul B; Dreyfuss, Alexandra; Yin, Sean; Zhang, Zhigang; Bai, Xing; Berry, Sean L; Zinovoy, Melissa; Nusrat, Maliha; Pappou, Emmanouil; Zelefsky, Michael J; Crane, Christopher H; Hajj, Carla
INTRODUCTION/UNASSIGNED:anorectal cancers previously treated with RT for prostate cancer. MATERIALS/METHODS/UNASSIGNED:We conducted a single-institution retrospective study of men treated with RT for rectal or anal cancer after prior prostate RT. Toxicity data were collected. Treatment plans were extracted to assess doses to organs at risk and target coverage. Cumulative incidence was calculated for local and distant progression. Kaplan-Meier curves were used to estimate overall survival (OS) and progression-free survival (PFS). RESULTS/UNASSIGNED:We identified 26 patients who received anorectal RT after prostate cancer RT: 17 for rectal cancer and 9 for anal cancer. None had metastatic disease. Prior prostate RT was delivered using low dose rate brachytherapy (LDR), external beam RT (EBRT), or EBRT + LDR. RT for rectal cancer was delivered most commonly using 50.4Gy/28 fractions (fr) or 1.5 Gy twice-daily to 30-45 Gy. The most used RT dose for anal cancer was 50Gy/25 fr. Median interval between prostate and anorectal RT was 12.3 years (range:0.5 - 25.3). 65% and 89% of rectal and anal cancer patients received concurrent chemotherapy, respectively. There were no reported ≥Grade 4 acute toxicities. Two patients developed fistulae; one was urinary-cutaneous after prostate LDR and 45Gy/25fr for rectal cancer, and the other was recto-vesicular after prostate LDR and 50Gy/25fr for anal cancer. In 11 patients with available dosimetry, coverage for anorectal cancers was adequate. With a median follow up of 84.4 months, 5-yr local progression and OS were 30% and 31% for rectal cancer, and 35% and 49% for anal cancer patients, respectively. CONCLUSION/UNASSIGNED:RT for anorectal cancer after prior prostate cancer RT is feasible but should be delivered with caution since it poses a risk of fistulae and possibly bleeding, especially in patients treated with prior LDR brachytherapy. Further studies, perhaps using proton therapy and/or rectal hydrogel spacers, are needed to further decrease toxicity and improve outcomes.
PMCID:9521738
PMID: 36185296
ISSN: 2234-943x
CID: 5529662
International journal of radiation oncology biology physics. 2022:114(3):S33-S33.DOI:

Quantitative Relaxometry for Target Localization and Response Assessment in Ultra-Hypofractionated MR-Guided Radiotherapy to the Prostate and DIL [Meeting Abstract]

Subashi, E.; LoCastro, E.; Apte, A.; Zelefsky, M. J.; Tyagi, N.
ISI:000892639302093
ISSN: 0360-3016
CID: 5531382